Browse Category

NYSE:STZ News 12 December 2025 - 21 January 2026

Constellation Brands (STZ) stock cools in premarket after Tuesday pop — what matters now

Constellation Brands (STZ) stock cools in premarket after Tuesday pop — what matters now

Constellation Brands shares fell 0.5% to $162.87 in premarket trading Wednesday after a 4.47% jump Tuesday, bucking a broader market selloff. The company faces pressure from weaker beer demand among Hispanic consumers, higher aluminum packaging costs, and a 3% drop in quarterly beer depletions. A $1.02 per share dividend will be paid Feb. 12 to holders of record Jan. 29.
Constellation Brands stock dips in premarket after earnings beat — what investors watch on the call

Constellation Brands stock dips in premarket after earnings beat — what investors watch on the call

Constellation Brands shares fell 2.2% premarket to $140.49 after the company cut its full-year earnings outlook despite beating profit estimates. Net sales dropped 10% to $2.22 billion for the quarter ended Nov. 30. Beer shipments fell 2.2%, with Modelo Especial depletions down 4% and Corona Extra down nearly 9%. The board declared a $1.02 quarterly dividend, payable Feb. 12.
Constellation Brands Stock (STZ) News Today: Why Shares Are Rebounding, What Wall Street Forecasts Next, and the Key Catalysts Into 2026 (Dec. 23, 2025)

Constellation Brands Stock (STZ) News Today: Why Shares Are Rebounding, What Wall Street Forecasts Next, and the Key Catalysts Into 2026 (Dec. 23, 2025)

Constellation Brands, Inc. (NYSE: STZ) is ending 2025 the way it spent much of the year: as one of the market’s most debated “defensive” stocks. On December 23, 2025, STZ was trading around $141.74, a level that reflects a sharp rebound from the mid-$130s area and puts the beer, wine, and spirits giant back in the spotlight for momentum traders and long-term investors alike. MarketWatch+1 The big question behind today’s move is the same one that’s been haunting the stock for months: Is Constellation Brands stock in a real turnaround—or just bouncing because it got too cheap and too hated?
23 December 2025
Constellation Brands (STZ) Stock Today: Latest News, Analyst Forecasts, and What Investors Are Watching on December 12, 2025

Constellation Brands (STZ) Stock Today: Latest News, Analyst Forecasts, and What Investors Are Watching on December 12, 2025

Published: December 12, 2025Constellation Brands, Inc. (NYSE: STZ ) — the US owner of the Corona and Modelo beer franchises — is back in focus for investors after a sharp 2025 drawdown, a recent two-day rebound, and a growing debate on what “normal” demand looks like for premium imported beer in a pressured consumer environment.MarketWatch+ 3Constellation Brands, Inc.+ 3DRY+ 3 As of early afternoon trading on Friday, Dec. 12 , STZ shares were around $148 , down roughly 0.8% from the prior close after opening near $150 . Below is a detailed roundup of today’s price action , the freshest
12 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop